ÂÜÀòÂÒÂ×

Paul Thorning is an accomplished executive with extensive experience in the pharmaceutical industry. As CEO of Crystec Pharma since September 2007, Paul has been instrumental in the company's growth and development. Currently, Paul serves as a Director at Inhalis Therapeutics SA, where a team is focused on advancing Inhalis101, a novel inhaled triple PI3K-mTOR-BRD4 inhibitor aimed at treating Idiopathic Pulmonary Fibrosis, Lung Cancer, and other fibrotic diseases. Paul has previously held leadership roles at the Institute of Pharmaceutical Innovation and CORD in Tanzania, as well as serving as Business and Market Research Director at AstraZeneca. Paul holds an MBA from Manchester Metropolitan University and a BSc in Mechanical Engineering from The University of Manchester.